Jomo with family

About Jomo

In 2019, Jomo Martin Nkunika turned 40. This Maryland based family man has led an active life full of vigor. He loves God, loves people, and loves life…

Learn More


We would like to thank you in advance for any financial support you can provide along with continued prayers and well wishes…

Learn More

About ALS

According to the Mayo Clinic, ALS affects the nerve cells in the brain and spine that control muscle movement. It doesn’t discriminate and affects people of

Learn More

As a person with a terminal disease, I applaud @US_FDA for exercising regulatory flexibility to give patients facing a terminal disease the chance to choose with their doctor whether to try a therapy that is safe and may help them. And I hope it will happen more often.


We are HOF (1966), 2x MVP, 18x All-Star Ted Williams days away from #LouGehrigDay!!!

Who's your favorite 9?

Attn: @RedSox, @MLB, @GordonEdes, @RedSoxFund, @BostonStrong_34, @BGlobeSports, @PeteAbe, @LeighMontville

The investigator at the Healey & AMG Center for ALS at Massachusetts General Hospital spoke to the CENTAUR open-label extension and AMX0035’s development.

Followers....want to take 2 minutes and help ALS patients? Click the link below 👇and sign to help ALS patients gain access to #AMX0035 from the ⁦@US_FDA⁩ ⁦@iamalsorg⁩ ⁦@alsassociation⁩


ALS Association Advocacy Action Center

Exciting positive results @US_FDA approve this! Amylyx Pharmaceuticals Announces New England Journal of Medicine Publication of Pivotal AMX0035 Data Demonstrating Statistically Significant Benefit in People with ALS | Business Wire

Join us tomorrow as our co-founders and co-CEOs, Joshua Cohen and Justin Klee, speak at @ALSFlorida’s #ALS Hope and Help Symposium! Register here to hear a little about Amylyx and from other great speakers:

We've reached a big regulatory milestone: Prosetin received Orphan Drug Designation for the treatment of ALS from the FDA. We break down what orphan status means, why it’s important, & what it means for Prosetin’s potential clinical development.

“- In Responder analysis, 80% of rapid progressor patients treated with AstroRx® were identified as responders.”


Kadimastem Reports Positive Interim Results of Cohort B of its AstroRx® Phase 1/2a Clinical Trial in ALS

The fact that patients—especially terminally ill patients—have to be patient advocates is insane. We will all be patients one day so why isn’t our default building patient-centric systems with baseline principles of providing the best care to all and speeding cures for all.

Load More...